Lv41
502 积分 2024-01-08 加入
Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279
10小时前
待确认
CD30+ High Grade Neoplasm With Expression of β‐HCG and T‐Cell Markers: Hybrid Germ Cell Tumor and T‐Cell Lymphoma?
11天前
已完结
SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions
1个月前
已关闭
Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience
1个月前
已完结
Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities
2个月前
已完结
Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects
2个月前
已完结
Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis
2个月前
已完结
Biopharmaceutical Switching in Psoriasis Treatment
3个月前
已完结
Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis
3个月前
已完结
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
